ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
November 01 2022 - 7:15AM
Business Wire
ADC Therapeutics SA (NYSE: ADCT) today announced the appointment
of Kristen Harrington-Smith as Chief Commercial Officer, effective
November 17, 2022. The Company also announced the appointment of
Peter Graham as Chief Legal Officer, effective November 1, 2022.
Both Ms. Harrington-Smith and Mr. Graham will serve on the
Company’s leadership team.
Kristen Harrington-Smith appointed as Chief Commercial
Officer
“We are delighted to welcome Kristen to ADC Therapeutics. She
has an extraordinary commercial background in the DLBCL landscape
having led the commercial teams for serious hematological diseases,
including major launches of innovative cell therapy products. We
have complete conviction that Kristen is the right leader to
maximize the potential of ZYNLONTA® and take our commercial
organization to the next level,” said Ameet Mallik, Chief Executive
Officer of ADC Therapeutics. “We would like to sincerely thank
Jennifer Herron for her strong dedication and her many
contributions to the Company, including building the commercial
organization and the launch of ZYNLONTA. We are pleased that
Jennifer will stay at the Company through mid-December to ensure a
smooth transition.”
Ms. Harrington-Smith is a seasoned leader with over 20 years of
experience in the pharmaceutical industry. Most recently, she has
served as Chief Commercial Officer of Immunogen where she has been
responsible for building the commercial organization and preparing
for the launch of its first commercial product. Prior to that, she
served as Vice President and Head, US Hematology at Novartis
Pharmaceuticals, where she led the teams responsible for a
portfolio of therapies in both malignant and non-malignant
hematologic diseases including diffuse large B-cell lymphoma
(DLBCL), acute myeloid leukemia, chronic myeloid leukemia, and
myelodysplastic syndrome. In previous roles of increasing seniority
at Novartis, Ms. Harrington-Smith was Vice President and Head, US
CAR-T, responsible for the commercial launch of Kymriah®, the first
CAR-T cell therapy for both DLBCL and acute lymphoblastic leukemia,
building the management, sales, marketing, and market access teams,
and supporting the launch of Gilenya® for the treatment of multiple
sclerosis. Ms. Harrington-Smith received an MBA from the
Kenan-Flagler Business School at the University of North Carolina
and a BA from Williams College.
“ADC Therapeutics is a long-standing innovative leader in the
ADC space with a robust pipeline, and I am thrilled to join the
company at this exciting time of growth,” said Ms.
Harrington-Smith. “ZYNLONTA is well-positioned in the DLBCL market,
and I have great confidence in its future growth prospect in the
third-line setting as well as the potential to expand and serve the
unmet medical needs in earlier line DLBCL patients.”
Peter Graham appointed as Chief Legal Officer
“Peter’s extensive global experience will be vital as our ADCs
progress toward regulatory, commercial and collaboration
milestones,” said Mr. Mallik. “I’m pleased to welcome Peter to our
team and look forward to leveraging his deep legal and
transactional expertise around our broad ADC technology platform
and capabilities.”
Mr. Graham is a senior legal executive with over 25 years of
legal, compliance and executive management experience primarily in
publicly traded biotechnology, pharmaceutical and medical device
companies. From 2015 until its sale to Halozyme Therapeutics, Inc.
in 2022, Mr. Graham served as Executive Vice President, General
Counsel, Chief Compliance Officer, Human Resources and Secretary
for Antares Pharma, Inc., a commercial-stage specialty
pharmaceutical and combination product company. Previously, he
served as Executive Vice President, General Counsel, Chief
Compliance Officer and Global Human Resources at Delcath Systems,
Inc., a combination products company focused on cancers of the
liver. Earlier in his career, Mr. Graham held various legal and
compliance executive leadership roles at ACIST Medical Systems,
Inc., E-Z-EM, Inc., and AngioDynamics, Inc. Mr. Graham received his
J.D. from Yeshiva University’s Benjamin N. Cardozo School of Law
and his BA in Political Science from the University of
Wisconsin-Madison.
“ADC Therapeutics has demonstrated impressive progress and
growth thanks to its talented team and rich pipeline of promising
ADCs,” said Mr. Graham. “I am excited to join such a dynamic team
and look forward to supporting the Company’s strategy with
effective legal counsel and bringing hope to patients and families
affected by cancer.”
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large b-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a pivotal Phase 2 trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics
has multiple ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221031005826/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com +44 7879 627205
Amanda Loshbaugh ADC Therapeutics
Amanda.Loshbaugh@adctherapeutics.com +1 917-288-7023
Media Mary Ann Ondish ADC Therapeutics
maryann.ondish@adctherapeutics.com +1 914-552-4625
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2023 to Apr 2024